Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
It is still not clear whether rifaximin can prevent the progression of liver cirrhosis,
reduce the overall complications and improve the survival in patients with decompensated
cirrhosis. This is a multi-center open-labelled randomized prospective study to evaluate the
efficacy and safety of rifaximin in preventing the progression and complications in cirrhotic
patients, and explore its reasonable dosage and possible mechanism. A total of 150 patients
with decompensated liver cirrhosis will be enrolled in the study and randomly divided into
three groups (the control group (A), the low-dose rifaximin treatment group (B), and
conventional dose rifaximin treatment group (C)) with a ratio of 1:2:2. The patients in group
B are given rifaximin with the dose of 600mg/d (600mg, qd) for 24 weeks, and the patients in
group C are delivered 1200mg/d (600mg, bid) of rifaximin .During the entire study period, all
other therapeutic strategies are kept unchanged in all the groups as long as possible. The
proportion of patients with progression of cirrhosis, the incidence of total complications
and each complication, survival rate and time, liver function and adverse events will be
compared among the three groups. This study might provide a new feasible method with clinical
application prospects for preventing the progression and reducing the incidence of liver
cirrhosis related complications, improve the prognosis of patients with decompensated liver
cirrhosis, and save medical resources.